Casodex - Nolvadex Combination

Phase 2

Completed

• Conditions: Gynaecomastia; Prostate Cancer
• Interventions: Drug: Casodex; Drug: Tamoxifen

• Registration Number: NCT00637871
• Lead Sponsor: AstraZeneca

Brief Summary

This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex. The aim of the study is to assess the optimal dose of nolvadex which will reduce the breast tissue adverse effects without reducing the efficacy of Casodex.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-11
• Primary Completion: 2005-06
• Study Completion: 2005-08
• Study First Submitted: 2008-03-12
• Study First Submitted QC: 2008-03-17
• Study First Posted: 2008-03-18
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-21
• Last Update Posted: 2011-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects with adenocarcinoma of the prostate gland but with no evidence of distant metastasis. The stage of disease should be T1-T4, any N, M0 confirmed histologically or cytologically
• Subjects in need of immediate hormonal therapy.
• PSA equal or above 4 ng/ml

Exclusion Criteria

• Presence of gynaecomastia and/or breast pain at screening visit
• Any previous endocrine therapy for prostate cancer other than neoadjuvant LHRH therapy prior to primary therapy of curative intent.
• Current use, or within the previous 6 months, of any medication known to have a high risk of causing gynaecomastia .
• Previous mastectomy or radiation to chest wall

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Casodex	-
2	Tamoxifen	-